SML1896
VH298
≥98% (HPLC), VHL-HIF-α interaction disrupter, powder
동의어(들):
(2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
Assay:
≥98% (HPLC)
Form:
powder
제품 이름
VH298, ≥98% (HPLC)
ligand
VH298
Quality Segment
assay
≥98% (HPLC)
form
powder
reaction suitability
reagent type: ligand
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
SMILES string
[s]1cnc(c1c2ccc(cc2)CNC(=O)[C@H]3N(C[C@@H](C3)O)C(=O)[C@@H](NC(=O)C4(CC4)C#N)C(C)(C)C)C
InChI key
NDVQUNZCNAMROD-RZUBCFFCSA-N
Biochem/physiol Actions
VH298 is a cell-permeable small molecule that disrupts the interaction of VHL with Hypoxia-inducible factor HIF-α, stabilizing HIF-α and inducing a hypoxic response.
VH298 is a cell-permeable small molecule that disrupts the interaction of VHL with Hypoxia-inducible factor HIF-α, stabilizing HIF-α and inducing a hypoxic response. Hypoxia-inducible factors (HIFs) are oxygen-sensitive transcription factors that regulate hypoxic signalling. They are regulated by oxygen-dependent prolyl hydroxylase domain (PHD) enzymes and polyubiquitination by the von Hippel–Lindau (VHL) Cullin RING E3 ubiquitin ligase complex. Unlike many PHD inhibitors, which have off-target effects, VH298 acts downstream of the PHD enzymes, inhibiting the VHL:HIF-α interaction. VH298 had a Kd of 90 nM. VH298 was shown to induce HIF transcriptional activity, to increase accumulation of HIF-α in HeLa cells and to stimulate erythropoietin production in RCC4 cells.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable